Centromere 17 copy number alteration negative prognostic factor in invasive breast cancer?

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 9, 2012, Pages 993-1000

  Petroni, Stella ^a,b   Addati, Teresa ^a   Mattioli, Eliseo ^a   Caponio, Maria Angela ^a   Quero, Carmela ^a   Rubini, Vincenza ^a   Giotta, Francesco ^b   Simone, Giovanni ^a  

^a Clinical Experimental Oncology Unit   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; CENTROMERE; CHROMOSOME 17; CHROMOSOME ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CENTROMERE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84866524076     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0327-OA     Document Type: Article

References (35)

1. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005; 11(18):6598-"6607. (Pubitemid 41339000)
2. Shah SS, Wang Y, Tull J, Zhang S. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma. Diagn Mol Pathol. 2009;18(1):30-"33.
3. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20(14):3095-"3105. (Pubitemid 34791099)
4. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13(1):63-"72. (Pubitemid 26248546)
5. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in nodenegative breast carcinomas. J Clin Oncol. 1997;(8):2894-"2904. (Pubitemid 27330017)
6. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13(7):1036-"1043.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-"182. (Pubitemid 17231334)
8. Ménard S, Balsari A, Casalini P, et al. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res. 2002;8(2): 520-"525. (Pubitemid 34193972)
9. Bianco AR, De Laurentiis M, Carlomagno C, et al. 20 years update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy. Clin Cancer Res. 2003;9: 1039-"1046. (Pubitemid 36323709)
10. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Nat Cancer Inst. 2003;95(2):142-"153. (Pubitemid 36193263)
11. Tsukamoto F, Miyoshi Y, Egawa C, et al. Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer. 2001;93(2):165-"170. (Pubitemid 32322173)
12. Reinholz MM, Bruzek AK, Visscher DW, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009;10(3):267-"277.
13. Bose S, Mohammed M, Shintaku P, Rao PN. Her-2/neu gene amplification in low to moderately expressing breast cancers: Possible role of chromosome 17/Her-2/neu polysomy. Breast J. 2001;7(5):337-"344. (Pubitemid 33101639)
14. Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer. 2007;43(16):2339-"2344. (Pubitemid 47625971)
15. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009;22(9):1169-"1175.
16. Marchió C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer: A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219(1): 16-"24.
17. Viale G. Be precise: The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol. 2009;219(1):1-"2.
18. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: Analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 2010;120(1):1-"7.
19. PathVision. HER-2 DNA probe kit [pakage insert]. Downers Grove, IL: Vysis; 2002.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: The value of histological grades in breast cancer - experience from a large study with long-term follow-up. Histopathology. 1991;19:403-"410.
21. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-"1329.
22. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations forhuman epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-"43. (Pubitemid 46174133)
23. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Arch Pathol Lab Med. 2009;133(4):611-"612.
24. McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002;117(6):935-"943. (Pubitemid 34564351)
25. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24(19):3032- "3038. (Pubitemid 46638937)
26. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: A study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005;7(2):R267-"R273.
27. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008;26(30):4869-"4874.
28. Bartlett JM, Desmedt C, Munro A, et al. Chromosome 17 polysomy: A unifying hypothesis underlying benefit from adjuvant anthracyclines? Cancer Res. 2009;69(suppl 2):11.
29. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 2006;5:2572-"2579. (Pubitemid 44650922)
30. Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol. 2009;22(8):1044-"1048.
31. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29(9):1221-"1227. (Pubitemid 41232996)
32. Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010;28(28):4307-"4315.
33. Keam B, Im SA, Lee KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13(2):R22.
34. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol. 2010; 41(6):914-"917.
35. Ross JS. Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference? J Clin Oncol. 2010;28(28):4293-"4295.